Developmental Pharmacogenetics of CYP2D6 in Chinese Children: Loratadine as a Substrate Drug

Li, Qian; Wu, Yue‐E; Wang, Kai; Shi, Haiyan; Zhou, Yue; Zheng, Yi; Hao, Guo‐Xiang; Yi-Lei, Yang; Su, Le-Qun; Wang, Wenqi; Yang, Xingmei; Zhao, Wei

doi:10.3389/fphar.2021.657287

Cited by 2 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Maturation rates are difficult to generalize, and enzyme-specific information needs to be determined for an accurate estimate of drug metabolism including clinical conditions such as sepsis and complex surgery, nutritional state and diet (infant formula versus breast milk), polymorphism and even antenatal exposure to cigarette smoke ( Czekaj et al, 2005 ; Blake et al, 2006 ; Allegaert, 2017 ; Li et al, 2021 ).…”

Section: Drug Disposition In Premature Neonatesmentioning

confidence: 99%

See 1 more Smart Citation

The Blind Spot of Pharmacology: A Scoping Review of Drug Metabolism in Prematurely Born Children

et al. 2022

View full text Add to dashboard Cite

The limit for possible survival after extremely preterm birth has steadily improved and consequently, more premature neonates with increasingly lower gestational age at birth now require care. This specialized care often include intensive pharmacological treatment, yet there is currently insufficient knowledge of gestational age dependent differences in drug metabolism. This potentially puts the preterm neonates at risk of receiving sub-optimal drug doses with a subsequent increased risk of adverse or insufficient drug effects, and often pediatricians are forced to prescribe medication as off-label or even off-science. In this review, we present some of the particularities of drug disposition and metabolism in preterm neonates. We highlight the challenges in pharmacometrics studies on hepatic drug metabolism in preterm and particularly extremely (less than 28 weeks of gestation) preterm neonates by conducting a scoping review of published literature. We find that >40% of included studies failed to report a clear distinction between term and preterm children in the presentation of results making direct interpretation for preterm neonates difficult. We present summarized findings of pharmacokinetic studies done on the major CYP sub-systems, but formal meta analyses were not possible due the overall heterogeneous approaches to measuring the phase I and II pathways metabolism in preterm neonates, often with use of opportunistic sampling. We find this to be a testament to the practical and ethical challenges in measuring pharmacokinetic activity in preterm neonates. The future calls for optimized designs in pharmacometrics studies, including PK/PD modeling-methods and other sample reducing techniques. Future studies should also preferably be a collaboration between neonatologists and clinical pharmacologists.

show abstract

Section: Drug Disposition In Premature Neonatesmentioning

confidence: 99%

“…In vivo CYP2D6 metabolism has been investigated in premature neonates using tramadol as substrate ( Allegaert et al, 2008a ; 2008b ). Here, PMA and CYP2D6 polymorphisms ( Li et al, 2021 ) was found to determine the O-demethylation activity in the preterm neonates.…”

Section: Exploring the Available Data On Premature Neonates: An Examp...mentioning

confidence: 99%

The Blind Spot of Pharmacology: A Scoping Review of Drug Metabolism in Prematurely Born Children

et al. 2022

View full text Add to dashboard Cite

show abstract

Categorization of Cytochrome P4502D6 Activity Score by Urinary Amphetamine/Methamphetamine Ratios

Chaichana¹,

Khamenkhetkarn²,

Sastraruji

et al. 2022

Metabolites

View full text Add to dashboard Cite

Methamphetamine (MA) level in urine has been used for judgment in MA consumption. Metabolism and intoxication of MA are correlated with the activity of cytochrome P450 2D6 (CYP2D6). The activity score (AS) is a potential tool for predicting exposure and personalized dose of drugs metabolized by CYP2D6. Prediction of the CYP2D6 activity score might be described as MA intoxication. The objective of this study was to categorize the CYP2D6 activity score using the urinary amphetamine (AM)/MA ratio. Urine samples (n = 23,258) were collected. The levels of MA and AM were determined by a gas chromatography–nitrogen–phosphorus detector. The log AS was calculated by an AM/MA ratio and classified into four groups following the percentile position: lower than the 2.5th, the 2.5th–the 50th, the 50th–97.5th, and greater than the 97.5th percentile, respectively. The AS value for males presented was less than 0.024, 0.024–0.141, 0.141–0.836, and greater than 0.836. Meanwhile, the AS values were revealed to be lower than 0.023, 0.023–0.148, 0.148–0.850, and higher than 0.850 for females. The AS value of CYP2D6 can be applied to describe the toxicity of MA in forensic crime scenes and relapse behavior.

show abstract

Developmental Pharmacogenetics of CYP2D6 in Chinese Children: Loratadine as a Substrate Drug

Cited by 2 publications

References 38 publications

The Blind Spot of Pharmacology: A Scoping Review of Drug Metabolism in Prematurely Born Children

The Blind Spot of Pharmacology: A Scoping Review of Drug Metabolism in Prematurely Born Children

Categorization of Cytochrome P4502D6 Activity Score by Urinary Amphetamine/Methamphetamine Ratios

Contact Info

Product

Resources

About